Recent Quotes (30 days)

You have no recent quotes
chg | %

Mirati Therapeutics Inc  

(Public, TSE:MYG)   Watch this stock  
TSE data delayed by 15 mins - Disclaimer
Currency in
Range     -
52 week 0.50 - 22.00
Open     -
Vol / Avg. 0.00/963.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -2.95
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -71.50% -86.82%
Return on average equity -80.80% -99.85%
Employees 52 -
CDP Score - -


9393 Towne Centre Dr Ste 200
SAN DIEGO, CA 92121-3070
United States - Map
+1-858-3323410 (Phone)
+1-302-6555049 (Fax)

Website links


Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL).

Officers and directors

Rodney W. Lappe Ph.D. Executive Chairman of the Board
Age: 61
Charles M. Baum M.D., Ph.D. President, Chief Executive Officer, Director
Age: 58
Jamie A. Donadio Chief Financial Officer, Senior Vice President
Age: 41
Isan Chen M.D. Chief Medical and Development Officer, Executive Vice President
Age: 52
Christopher C. LeMasters Executive Vice President, Chief Business Officer
James Christensen Senior Vice President, Chief Scientific Officer
Age: 46
Marcy Graham Vice President - Investor Relations and Corporate Communications
Bruce L.A. Carter Ph.D. Director
Age: 73
Michael G. Grey Director
Age: 64
Neil A. Reisman CPA, J.D. Director